upadacitinib Extended-Release Tablets

The main clinical indications of upadacitinib extended-release tablets are a variety of rheumatic and immune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, etc.
Atopic dermatitis: Upadacitinib is suitable for adults and pediatric patients aged 12 years and above with refractory moderate to severe atopic dermatitis that cannot be treated poorly by other systemic drugs (including hormones or biological agents) or are not suitable for these therapies.
Rheumatoid arthritis: Upadacitinib is suitable for adult patients with moderate to severe active rheumatoid arthritis who have an inadequate response or intolerance to one or more TNF blockers.
Psoriatic arthritis: Upadacitinib is suitable for adult patients with active psoriatic arthritis who have an inadequate response or intolerance to one or more TNF blockers.